DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2008/0175887 A1 Wang (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2008/0175887 A1 Wang (43) Pub US 2008O175887A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0175887 A1 Wang (43) Pub. Date: Jul. 24, 2008 (54) TREATMENT OF ASTHMA AND CHRONIC Mar. 2, 2007, provisional application No. 60/981,380, OBSTRUCTIVE PULMONARY DISEASE filed on Oct. 19, 2007, provisional application No. WITH ANT-PROLIFERATE AND 60/981,384, filed on Oct. 19, 2007. ANTI-NFLAMMATORY DRUGS Publication Classification (76) Inventor: Lixiao Wang, Medina, MN (US) (51) Int. Cl. A6IR 9/12 (2006.01) Correspondence Address: A63L/436 (2006.01) FINNEGAN, HENDERSON, FARABOW, GAR A6IP II/00 (2006.01) RETT & DUNNER A6M I5/00 (2006.01) LLP A6IF 2/82 (2006.01) 901 NEW YORKAVENUE, NW A6M 25/10 (2006.01) WASHINGTON, DC 20001-4413 A6M II/00 (2006.01) A63L/337 (2006.01) (21) Appl. No.: 11/942,459 (52) U.S. Cl. ........... 424/434; 514/291; 514/449; 424/43; 128/200.23; 128/203.15; 604/103.02; 623/1.42 (22) Filed: Nov. 19, 2007 (57) ABSTRACT Embodiments of the present invention provide a method for Related U.S. Application Data treatment of respiratory disorders such as asthma, chronic (60) Provisional application No. 60/860,084, filed on Nov. obstructive pulmonary disease, and chronic sinusitis, includ 20, 2006, provisional application No. 60/880,742, ing cystic fibrosis, interstitial fibrosis, chronic bronchitis, filed on Jan. 17, 2007, provisional application No. emphysema, bronchopulmonary dysplasia and neoplasia. 60/897.427, filed on Jan. 25, 2007, provisional appli The method involves administration, preferably oral, nasal or cation No. 60/903.529, filed on Feb. 26, 2007, provi pulmonary administration, of anti-inflammatory and anti sional application No. 60/926,850, filed on Apr. 30, proliferative drugs (rapamycin or paclitaxel and their ana 2007, provisional application No. 60/904,473, filed on logues). US 2008/0175887 A1 Jul. 24, 2008 TREATMENT OF ASTHMIA AND CHRONIC emphysema localized to the upper lung lobes are candidates OBSTRUCTIVE PULMONARY DISEASE for lung Volume reduction Surgery, where the upper lobes are WITH ANT-PROLIFERATE AND Surgically removed to restore the natural concavity and func ANTI-NFLAMMATORY DRUGS tion of the diaphragm. 0006 Acute exacerbation of asthma are often caused by CROSS REFERENCE TO RELATED spasm of the airways, or bronchoconstriction, causing Symp APPLICATIONS toms including Sudden shortness of breath, wheezing, and cough. Bronchospasm is treated with inhaled bronchodilators 0001. This application claims the benefit of priority under (anticholinergics such as ipratropium and beta-agonists Such 35 U.S.C. S 119 of U.S. Provisional Application No. 60/860, as albuterol). Patients inhale these medications into their 084, filed on Nov. 20, 2006, U.S. Provisional Application No. lungs as a mist, produced by either a nebulizer or a hand-held 607880,742, filed Jan. 17, 2007, U.S. Provisional Application meter dose (MDI) or dry powder (DPI) inhaler. Patients with No. 60/897,427, filed on Jan. 25, 2007, U.S. Provisional acute episodes may also be treated with oral or intravenous Application No. 60/903.529 filed on Feb. 26, 2007, U.S. steroids that serve to reduce the inflammatory response that Provisional Application No. 60/926,850 filed Apr. 30, 2007, exacerbates the condition. U.S. Provisional Application No. 60/904,473 filed Mar. 2, 0007 Asthma is a chronic respiratory disease character 2007, U.S. Provisional Application No. 60/981,380 filed Oct. ized by inflammation of the airways, excess mucus produc 19, 2007, and U.S. Provisional Application 60/981,384 filed tion and airway hyperresponsiveness, and a condition in Oct. 19, 2007, the disclosures of all of which are incorporated which airways narrow excessively or too easily respond to a by reference herein. stimulus. Asthma episodes or attacks cause narrowing of the airways, which make breathing difficult. Asthma attacks can FIELD OF THE INVENTION have a significant impact on a patient’s life, limiting partici 0002 The present invention relates to a method for treat pation in many activities. In severe cases, asthma attacks can ment of respiratory disorders such as asthma and chronic be life threatening. Presently, there is no know cure for obstructive pulmonary disease, including cystic fibrosis, asthma. interstitial fibrosis, chronic bronchitis, emphysema, bron 0008 According to the American Lung Association, there chopulmonary dysplasia and neoplasia. The method involves are approximately 20 million Americans with asthma in 2002. administration, preferably oral, nasal or pulmonary adminis Fourteen million of them were adults. Asthma resulted in tration, of anti-inflammatory and anti-proliferate drugs (rapa approximately 1.9 million emergency room visits in 2002. mycin or paclitaxel and their analogues). The estimated direct cost of asthma in the U.S. is S11.5 billions, which is spent on asthma medications, physician BACKGROUND OF THE INVENTION office visits, emergency room visits and hospitalizations. 0003 Chronic obstructive pulmonary disease (COPD) is a 0009. The causes of coronary heart disease and asthma are term used to classify two major airflow obstruction disorders: neointimal proliferation of Smooth muscle in arterial vessels chronic bronchitis and emphysema. Approximately 16 mil and in walls of airways. One aspect of the invention is to lion Americans have COPD, 80-90% of them were smokers deliverpaclitaxel or rapamycin and their analogues to the wall throughout much of their lives. COPD is a leading cause of of airways to treat the asthma and COPD. Drug coated stents death in the U.S., accounting for 122.283 deaths in 2003. The with these drugs have been approved for inhibiting the growth cost to the USA for COPD was approximately $20.9 billion in of the Smooth muscle cells in vascular arterial vessels. direct health care expenditures in 2003. Chronic bronchitis is 0010 Chronic sinusitis is an inflammation of the mem inflammation of the bronchial airways. The bronchial airways brane lining of one or more paranasal sinuses. Chronic sinusi connect the trachea with the lungs. When inflamed, the bron tis lasts longer than three weeks and often continues for chial tubes Secrete mucus, causing a chronic cough. Emphy months. In cases of chronic sinusitis, there is usually tissue sema is an overinflation of the alveoli, or air sacs in the lungs. damage. According to the Center for Disease Control (CDC), This condition causes shortness of breath. thirty seven million cases of chronic sinusitis are reported 0004. In emphysema, the alveolar sacs are overinflated as annually. a result of damage to the elastin skeleton of the lung. Inflam 0011 Chronic sinusitis is often difficult to treat success matory cells in emphysematous lung release elastase fully, however, as some symptoms persist even after pro enzymes, which degrade or damage elastin fibers within the longed courses of antibiotics. Steroid nasal sprays and pre lung matrix. Emphysema has a number of causes, including scribed Steroids are commonly used to treat inflammation in Smoking, exposure to environmental pollutants, alpha-one chronic sinusitis. When medical treatment fails, Surgery may antitrypsin deficiency, and aging. be the only alternative in treating chronic sinusitis. Presently, 0005. There are no therapies available today to halt the the most common Surgery done is functional endoscopic progression of COPD. Inhaled steroids have recently been sinus Surgery, in which the diseased and thickened tissues studied (Lung Health Study II) as a potential therapy to pre from the sinuses are removed to allow drainage. However, vent loss of lung function in emphysema patients. The study there is a need for better medicine for chronic sinusitis. concluded, however, that inhaled steroids failed to alter the 0012. The present invention provides a new method for decline in lung function over time. As patients lose lung treatment of respiratory disorders such as asthma, chronic function over time, they may become dependent on oxygen, obstructive pulmonary disease, and chronic sinusitis. The and eventually end up onventilators to assist with respiration. method involves administration, preferably oral, nasal or pull A relatively new treatment for patients with emphysema is monary administration, of anti-inflammatory and anti-prolif lung Volume reduction Surgery. Emphysema patients Suffer erate drugs (rapamycin or paclitaxel and their analogues). from air trapping in the lungs. This flattens the diaphragm, Embodiments of the present invention provides a pharmaceu impairing the ability to inhale and exhale. Patients with tical formulation comprising a drug for treatment of the res US 2008/0175887 A1 Jul. 24, 2008 piratory system, and an additive that enhances absorption of Sally, intrabronchially, transdermally, rectally, or via an the drug into tissue of body passages. impregnated vascular stent or balloon catheter into a body passage, wherein said drug is chosen from rapamycin and SUMMARY OF THE INVENTION analogues thereof and paclitaxel and analogues thereof. In 0013 Embodiments of the present invention are directed one aspect of this embodiment, the asthma and chronic to the treatment of respiratory disorders by intratracheal obstructive pulmonary disease to be treated is selected from administration of an effective amount of anti-inflammatory the group consisting of chronic bronchitis, cystic fibrosis, and anti-proliferate drugs (rapamycin or paclitaxel and their interstitial fibrosis, nasal and sinus dysplasia, bronchopulmo analogues). Respiratory disorders such as asthma, chronic nary dysplasia
Load more

Recommended publications
  • |||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka Et Al
    |||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka et al. 45) Date of Patent: Apr. 13, 1993 (54) COMPOSITION AND METHOD FOR 4,528,295 7/1985 Tabakoff .......... ... 514/562 X REDUCING ACETALDEHYDE TOXCTY 4,593,020 6/1986 Guinot ................................ 514/811 (75) Inventors: Masayoshi Matsuoka, Habikino; Go OTHER PUBLICATIONS Kito, Yao, both of Japan Sprince et al., Agents and Actions, vol. 5/2 (1975), pp. 73) Assignee: Takeda Chemical Industries, Ltd., 164-173. Osaka, Japan Primary Examiner-Arthur C. Prescott (21) Appl. No.: 839,265 Attorney, Agent, or Firn-Wenderoth, Lind & Ponack 22) Filed: Feb. 21, 1992 (57) ABSTRACT A novel composition and method are disclosed for re Related U.S. Application Data ducing acetaldehyde toxicity, especially for preventing (63) Continuation of Ser. No. 13,443, Feb. 10, 1987, aban and relieving hangover symptoms in humans. The com doned. position comprises (a) a compound of the formula: (30) Foreign Application Priority Data Feb. 18, 1986 JP Japan .................................. 61-34494 51) Int: C.5 ..................... A01N 37/00; A01N 43/08 52 U.S. C. ................................. ... 514/562; 514/474; 514/81 wherein R is hydrogen or an acyl group; R' is thiol or 58) Field of Search ................ 514/557, 562, 474,811 sulfonic group; and n is an integer of 1 or 2, (b) ascorbic (56) References Cited acid or a salt thereof and (c) a disulfide type thiamine derivative or a salt thereof. The composition is orally U.S. PATENT DOCUMENTS administered, preferably in the form of tablets. 2,283,817 5/1942 Martin et al.
    [Show full text]
  • Drug Releasing Coatings for Medical Devices
    (19) & (11) EP 2 500 046 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 19.09.2012 Bulletin 2012/38 A61L 29/16 (2006.01) A61L 31/16 (2006.01) (21) Application number: 11176688.7 (22) Date of filing: 16.05.2008 (84) Designated Contracting States: (72) Inventor: Wang, Lixiao AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Medina, MN Minnesota 55356 (US) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR (74) Representative: HOFFMANN EITLE Designated Extension States: Patent- und Rechtsanwälte AL BA MK RS Arabellastrasse 4 81925 München (DE) (30) Priority: 19.10.2007 US 981380 P 19.10.2007 US 981384 P Remarks: 19.11.2007 US 942452 •This application was filed on 05-08-2011 as a divisional application to the application mentioned (62) Document number(s) of the earlier application(s) in under INID code 62. accordance with Art. 76 EPC: •Claims filed after the date of receipt of the divisional 08767783.7 / 2 073 860 application (Rule 68(4) EPC). (71) Applicant: Lutonix, Inc. Maple Grove, MN 55369 (US) (54) Drug releasing coatings for medical devices (57) The invention relates to a medical device for de- bonding, and a part that has an affinity to the therapeutic livering a therapeutic agent to a tissue. The medical de- agent by van der Waals interactions. In embodiments, vice has a layer overlying the exterior surface of the med- the additive is water- soluble. In further embodiments, the ical device.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.625,916 B2 Kawasugi (45) Date of Patent: Dec
    US00762.5916B2 (12) United States Patent (10) Patent No.: US 7.625,916 B2 Kawasugi (45) Date of Patent: Dec. 1, 2009 (54) MEDICINAL COMPOSITION (56) References Cited (76) Inventor: Kaname Kawasugi, 26-10-405, U.S. PATENT DOCUMENTS Higashi-oi 5-chome, Shinagawa-ku 3,502,674. A 3/1970 Takamizawa et al. Tokyo (JP) 140-0011 4,687,777 A * 8/1987 Meguro et al. .............. 514,342 5,002.953 A * 3/1991 Hindley ......... ... 514,275 c - r 5,977.073 A * 1 1/1999 Khaled ........................ 514, 19 (*) Notice: Subject to any disclaimer, the term of this 6,166,219 A * 12/2000 Yamasaki et al. ........ 548/309.4 patent is extended or adjusted under 35 6.251926 B1* 6/2001 Momose et al. ............. 514,364 U.S.C. 154(b) by 122 days. 6,660,293 B2 * 12/2003 Giordano et al. ............ 424/439 (21) Appl. No.: 10/572,557 FOREIGN PATENT DOCUMENTS FR 2832O64 A1 * 5, 2003 (22) PCT Filed: Sep. 17, 2003 WO O2/O51441 T 2002 (86). PCT No.: PCT/UP03/11847 OTHER PUBLICATIONS Tamai, Hiroshi. “Diabetes and Vitamin Levels', Japanese Journal of S371 (c)(1), Clinical Medicine, vol. 57, No. 10, pp. 200-203, 1999. (2), (4) Date: Mar. 17, 2006 Hashizume, Naotaka, “Vitamin B1 Deficiency”. Igaku no Ayumi, vol. 198, No. 13, pp. 949-952, 2001. (87) PCT Pub. No.: WO2005/027967 * cited by examiner PCT Pub. Date: Mar. 31, 2005 Primary Examiner Kevin Weddington (74) Attorney, Agent, or Firm Oblon, Spivak, McClelland, Maier & Neustadt, L.L.P. (65) Prior Publication Data (57) ABSTRACT US 2007/O 10591.0 A1 May 10, 2007 A medicinal composition which comprises an insulin resis 51) Int.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,366,660 B2 Wang (45) Date of Patent: *Feb
    US008366660B2 (12) United States Patent (10) Patent No.: US 8,366,660 B2 Wang (45) Date of Patent: *Feb. 5, 2013 (54) DRUG RELEASING COATINGS FOR 5,135,516 A 8/1992 Sahatian et al. MEDICAL DEVICES 5,138,051 A 8/1992 Hughes et al. 5,151,413 A 9, 1992 Caufield et al. 5,162.333 A 11/1992 Failli et al. (75) Inventor: Lixiao Wang, Medina, MN (US) 5,164,399 A 11/1992 Failli et al. 5,177,203 A 1/1993 Failli et al. (73) Assignee: Lutonix, Inc., New Hope, MN (US) 5,194,447 A 3, 1993 Kao 5,196,596 A 3/1993 Abatjoglou Notice: Subject to any disclaimer, the term of this 5, 199,951 A 4/1993 Spears (*) 5,221,670 A 6/1993 Caufield patent is extended or adjusted under 35 5,221,740 A 6/1993 Hughes U.S.C. 154(b) by 0 days. 5,233,036 A 8/1993 Hughes 5,252,579 A 10, 1993 Skotnicki et al. This patent is Subject to a terminal dis 5,254,089 A 10/1993 Wang et al. claimer. 5,260,300 A 11, 1993 Hu 5,262.423 A 11/1993 Kao (21) Appl. No.: 13/042.207 5,269,770 A 12/1993 Conway et al. 5,302.584 A 4, 1994 Kao et al. Filed: Mar. 7, 2011 5,304,121 A 4/1994 Sahatian (22) 5,324,261 A 6/1994 Amundson et al. 5,346,893 A 9, 1994 Failli et al. (65) Prior Publication Data 5,349,060 A 9, 1994 Kao et al.
    [Show full text]
  • Pharmaceuticals and Medical Devices Safety Information No
    Pharmaceuticals and Medical Devices Safety Information No. 215 July 2005 Table of Contents 1. Important Safety Information ································································ 2 .1. Ethionamide ······················································································ 2 .2. Etodolac ···························································································· 5 .3. Gemcitabine Hydrochloride ····························································· 10 .4. Omeprazole, Omeprazole Sodium ·················································· 12 2. Revision of PRECAUTIONS (No.167) Tiaprofenic Acid (and 17 others) ·································································· 16 3. List of products subject to Early Post-marketing Phase Vigilance ·············································· 23 This Pharmaceuticals and Medical Devices Safety Information (PMDSI) is issued based on safety information collected by the Ministry of Health, Labour and Welfare. It is intended to facilitate safer use of pharmaceuticals and medical devices by healthcare providers. PMDSI is available on the Pharmaceuticals and Medical Devices Agency website (http://www.pmda.go.jp/english/index.html) and on the MHLW website (http://www.mhlw.go.jp/, Japanese only). Published by Translated by Pharmaceutical and Food Safety Bureau, Pharmaceuticals and Medical Devices Agency Ministry of Health, Labour and Welfare Pharmaceutical and Food Safety Bureau, Office of Safety, Ministry of Health, Labour and Welfare Pharmaceuticals and Medical
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Drug Information Sheet("Kusuri-No-Shiori") Draft
    Drug Information Sheet("Kusuri-no-Shiori")_Draft Internal Published: 10/2015 The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment. Brand name:Neurovitan Tablets Active ingredient:Octotiamine Riboflavin Pyridoxine hydrochloride Cyanocobalamin Dosage form:pale red tablet, diameter: 7.1 mm, thickness: 3.3 mm Print on wrapping:(face)ノイロビタン, f536, (back) ノイロビタン, ビタミン B 群配合錠, company mark Effects of this medicine This medicine is a formulation of vitamins B1, B2, B6 and B12 to supplement these vitamins in short supply and restore balance. It is usually used to supplement vitamins when they cannot be taken properly from food, or to treat neuralgia, myalgia/arthralgia and peripheral neuritis/peripheral nerve palsy caused by vitamin deficiency or metabolic abnormality. Before using this medicine, be sure to tell your doctor and pharmacist ・If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines. ・If you are pregnant or breastfeeding. ・If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.) Dosing schedule (How to take this medicine) ・Your dosing schedule prescribed by your doctor is<< to be written by a healthcare professional>> ・In general, for adults, take 1 to 3 tablets daily.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Phytochemical Study and Anticancer Potential of High Antioxidant Australian Native Plants
    Phytochemical Study and Anticancer Potential of High Antioxidant Australian Native Plants Author Sirdaarta, Joseph P Published 2016 Thesis Type Thesis (PhD Doctorate) School School of Natural Sciences DOI https://doi.org/10.25904/1912/1565 Copyright Statement The author owns the copyright in this thesis, unless stated otherwise. Downloaded from http://hdl.handle.net/10072/365567 Griffith Research Online https://research-repository.griffith.edu.au Griffith University Phytochemical study and anticancer potential of high antioxidant Australian native plants Principal supervisor: Dr Ian Edwin Cock Co-supervisor: Dr Sarah Ashmore By Joseph P Sirdaarta B. Food Science and Nutrition (Hons) School of Natural Sciences Griffith University Submitted in fulfilment of the requirements of the degree of Doctor of Philosophy On the April 11th 2016 Chapter 1 1 | P a g e Statement of Originality This work, entitled Phytochemical study and anticancer potential of high antioxidant Australian native plants, has not previously been submitted for a degree in any university. To the best of my knowledge and belief, the thesis contains no material previously published or written by another person except where due reference is made in the thesis itself. Joseph P Sirdaarta April 11th, 2016 Chapter 1 2 | P a g e Acknowledgements I would like to take this opportunity to thank the Lord Jesus Christ for giving me this opportunity to pursue my PhD. He has all my gratitude for his provisions and support through trying times. Furthermore, I would like to thank Griffith University for offering me the opportunity through scholarships to complete the program. I would like to thank my supervisors Dr Ian Cock and Dr Sarah Ashmore for their help and guidance.
    [Show full text]
  • Neurovitan Sugar Coated Tablets 1.3.3 LEAFLET Enclosed Below
    Neurovitan Sugar Coated Tablets 1.3.3 LEAFLET Enclosed below: Module 1 Page 1 CONFIDENTIAL ® ® ® نيوروڤيتان NEUROVITAN NEUROVITAN )فيتامينات خاصة باجلهازين العصبي والعضلي( (Complexe vitaminé Neuro musculaire) (Neuro - Musculo - Tropic Vitamin Complex) ACTION ACTION املفعول Neurovitan est une préparation multivitaminique Neurovitan is a multivitamin preparation containing نيوروڤيتان مستحضر مؤلف من عدة ڤيتامينات - اوكتوتيامني )مشتق من contenant: octotiamine, facilement absorbable, octotiamine, a readily absorbable and long-acting الثيامني( طويل املفعول وسريع اﻻمتصاص، ريبوفﻻفني )فيتامني بavec un dérivé de la thiamine à l’action retardée, thiamine derivative, riboflavine (B2), pyridoxine ،)2 بايريدوكسني هيدروكلورايد )فيتامني ب6(، وسيانوكوبوﻻمني )فيتامني .(riboflavine (B2), chlorhydrate de pyridoxine (B6), hydrochloride (B6), and cyanocobalamin (B12 ب12(، تتفاعل هذه العناصر احليوية بشكل معقول لتعطي تأثيرا ملحوظا avec cyanocobalamine (B12). These vital elements interact rationally to exert a على اجلهاز العصبي. .Ces éléments vitaux réagissent rationnellement pour marked effect on the nervous system التركيب exercer un effet notable sur le système nerveux. COMPOSITION كل قرص مغلف يحتوي على: :COMPOSITION Each sugar coated tablet contains اوكتوتيامني 25 ملغم 25 mg Chaque comprimé pélliculé contient: Octotiamine Octotiamine 25 mg بايريدوكسني )على شكل هيدروكلورايد( 40 ملغم Pyridoxine (as hydrochloride) 40 mg (Chlorhydrate) pyridoxine 40 mg ريبوفﻻفني 5ر2 ملغم 2.5 mg Riboflavine Riboflavine 2,5 mg سيانوكوبوﻻمني 25ر0 ملغم 0.25 mg Cyanocobalamin Cyanocobalamine
    [Show full text]
  • Monograph for Vitamin and Mineral Pharmaceutical Products Review and Approval
    維生素及礦物質製劑基準草案(英文)-980203 Monograph for Vitamin and Mineral Pharmaceutical Products Review and Approval I. Scope 1. The Vitamin and Mineral products established by this Monograph represent the single or complex, orally-taken pharmaceutical products. 2. If the daily dosage limitation of an ingredient contained in a product is exceeded the daily dosage limitation for OTC Drug, the product is classified as Prescription Drug. 3. If a product, which contains the vitamins not listed in this Monograph, or the vitamin ingredient sources or salts not listed in this Monograph, its classification is to be reviewed case by case. 4. If a product, which indication scope is beyond the indications listed for OTC Drug and Quasi Drug (Category B) in this Monograph, its classification is to be reviewed case by case. 5. The orally-taken products established by this Monograph represent dosage forms, such as Capsules, Tablets, Syrup, Solution, etc. And, such dosage form must be the approved form to be used in Vitamin and Mineral products. II. Compounding Ingredients 1. The category and potency of compounding ingredients： (1) The compounding Vitamin and Mineral ingredients established by this Monograph (also called as compound ingredients) are presented in Table I. 1 維生素及礦物質製劑基準草案(英文)-980203 (2) The Table I establishes the upper daily dosage limitation of compounding ingredients of OTC Drug or Quasi Drug (Category B). (3) If the daily dosage limitation of any ingredient in a product is exceeded the upper daily dosage limitation of Quasi Drug in Table I, the product is classified as OTC Drug. If the daily dosage limitation of any ingredient in a product is exceed the upper daily dosage limitation of OTC Drug in Table I, the product is classified as Prescription Drug.
    [Show full text]